Rhamy Zeid
Chief Scientific Officer Nexo Therapeutics
Seminars
Wednesday 21st October 2026
Fireside Chat: Interpreting Preclinical Safety Data to Support First in Human & Early Clinical Decisions for Covalent Drugs
4:30 pm
- How are different organizations assessing covalent safety risk prior to first in human studies, and how are these assessments informing starting dose and escalation strategy?
- How reliably do preclinical toxicity and target engagement signals translate across species for covalent drugs, and where do current models consistently fail to predict clinical outcomes?
- What practical criteria are teams using today to progress covalent candidates into the clinic in the absence of definitive, predictive safety models?
